En Es
Categories

Fluidigm

Fluidigm Corporation focuses on the most pressing needs in translational and clinical research, including cancer, immunology, and immunotherapy. Using proprietary CyTOF and microfluidics technologies, the company develops, manufactures, and markets multi-omic solutions to drive meaningful insights in health and diseas ...
Products Covid-19Summary
Close

Covid-19 Fluidigm

Clinical Laboratory

SARS-CoV-2 RT-PCR Assay
Advanta Dx SARS-CoV-2 RT-PCR Assay

The Advanta Dx SARS-CoV-2 RT-PCR Assay is a qPCR-based test that, by taking advantage of Fluidigm proprietary microfluidics technology and the Juno and Biomark HD systems, enables reliable, high-capacity testing of saliva samples from patients suspected by their health care providers of COVID-19 (coronavirus) infection to support diagnostic decision making. The assay has been authorized for use under FDA Emergency Use Authorization (EUA) and is CE-IVD marked under the In Vitro Diagnostics Directive (IVDD 98/79/EC).
More details

RT-PCR Kit
Advanta RT-PCR Kit

The Advanta RT-PCR Kit—192.24 provides scalable, high-throughput pathogen detection through nanoliter-scale volumes with walkaway automation. Using the 192.24 Dynamic Array IFC (integrated fluidic circuit) enables rapid data acquisition of up to 192 samples across 24 targets: up to 4,608 reactions every 35 minutes. The kit enables probe-based qPCR of 1,920 samples and combines reverse transcription and preamplification in a single step.
More details

SARS-CoV-2 Mutation Assay Panel
Advanta SARS-CoV-2 Mutation Assay Panel

The Fluidigm RT-PCR based Advanta SARS-CoV-2 Mutation Assay Panel is an expansion of the Advanta pathogen detection portfolio and can concurrently detect the reference virus and mutations associated with six Variants of Concern identified by the CDC and WHO. Leveraging our proprietary microfluidics technology along with the Biomark™ HD platform and an IFC controller, the detection of these new mutations is performed seamlessly without the need for additional integrated fluidic circuits (IFCs), run reagents or sample volume, providing more data without additional labor. As the virus continues to evolve, the assay’s open design enables this solution to evolve along with it.
More details
Close

About Fluidigm

Fluidigm Corporation focuses on the most pressing needs in translational and clinical research, including cancer, immunology, and immunotherapy. Using proprietary CyTOF and microfluidics technologies, the company develops, manufactures, and markets multi-omic solutions to drive meaningful insights in health and disease, identify biomarkers to inform decisions, and accelerate the development of more effective therapies. Its customers are leading academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories worldwide.
FaceBook Twitter Google+ Linked in
Immune Profiling System

Immune Profiling System

Model: Maxpar Direct Immune Profiling System
Request Information

Description:

The Maxpar Direct Immune Profiling System is the first complete sample-to-answer solution for high-dimensional immune profiling of human PBMC and whole blood. Designed as a simple, single-tube workflow, the system brings together CyTOF technology on the Helios system, a dry 30-marker antibody panel and automated Maxpar Pathsetter software so you can easily count 37 immune cell populations with performance you can trust.

Features

Features

• Comprehensive: Profile 37 immune cell populations from PBMC or whole blood with an optimized 30-marker panel.
• Efficient: Simple single-tube workflow with pushbutton reporting. Just add sample and go.
• Reliable: Produce consistent results lot-to-lot, run-to-run and site-to-site. Request Information

Send A Message To This Supplier

* Required Information
* Email
To
Fluidigm (Immune Profiling System)
* Message

Copyright © 2000-2021 TradeMed.com. All rights reserved. | Terms And Conditions